Nusinersen, the first approved treatment for SMA, is an intrathecally administered antisense oligonucleotide (ASO) designed to bind to the pre-mRNA of SMN2 and promote the inclusion of exon 7 [9]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.